Selected research
Industry Research
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Research Report 2026
Market perspective
The global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Post-Polycythemia Vera Myelofibrosis (PPV-MF) market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Post-Polycythemia Vera Myelofibrosis (PPV-MF) include Novartis AG, Merck & Co Inc, AbbVie Inc, Sun Pharma Advanced Research Company Ltd, Promedior Inc, NS Pharma Inc, MEI Pharma Inc, MedImmune LLC and JW Pharmaceutical Corp, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Post-Polycythemia Vera Myelofibrosis (PPV-MF).
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market by Company
Novartis AG
Merck & Co Inc
AbbVie Inc
Sun Pharma Advanced Research Company Ltd
Promedior Inc
NS Pharma Inc
MEI Pharma Inc
MedImmune LLC
JW Pharmaceutical Corp
Italfarmaco SpA
Incyte Corp
Gilead Sciences Inc
F. Hoffmann-La Roche Ltd
CTI BioPharma Corp
Celgene Corp
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Type
Idelalisib
Givinostat
Glasdegib
Durvalumab
IMG-7289
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Application
Hospital
Clinic
Others
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Post-Polycythemia Vera Myelofibrosis (PPV-MF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Post-Polycythemia Vera Myelofibrosis (PPV-MF) and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Post-Polycythemia Vera Myelofibrosis (PPV-MF).
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Post-Polycythemia Vera Myelofibrosis (PPV-MF) companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Idelalisib
- Givinostat
- Glasdegib
- Durvalumab
- IMG-7289
- Others
Applications
- Hospital
- Clinic
- Others
Companies covered
- Novartis AG
- Merck & Co Inc
- AbbVie Inc
- Sun Pharma Advanced Research Company Ltd
- Promedior Inc
- NS Pharma Inc
- MEI Pharma Inc
- MedImmune LLC
- JW Pharmaceutical Corp
- Italfarmaco SpA
- Incyte Corp
- Gilead Sciences Inc
- F. Hoffmann-La Roche Ltd
- CTI BioPharma Corp
- Celgene Corp
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Idelalisib
- 2.2.3 Givinostat
- 2.2.4 Glasdegib
- 2.2.5 Durvalumab
- 2.2.6 IMG-7289
- 2.2.7 Others
- 2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hospital
- 2.3.3 Clinic
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Breakdown Data by Type
- 3.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Type (2021-2026)
- 3.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Type (2027-2032)
4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Breakdown Data by Application
- 4.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Application (2021-2026)
- 4.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Perspective (2021-2032)
- 5.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Growth Trends by Region
- 5.2.1 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Historic Market Size by Region (2021-2026)
- 5.2.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Forecasted Market Size by Region (2027-2032)
- 5.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Dynamics
- 5.3.1 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Trends
- 5.3.2 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Drivers
- 5.3.3 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Challenges
- 5.3.4 Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue
- 6.1.1 Global Top Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players by Revenue (2021-2026)
- 6.1.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Revenue Market Share by Players (2021-2026)
- 6.2 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Post-Polycythemia Vera Myelofibrosis (PPV-MF) Head Office and Area Served
- 6.4 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Players, Product Type & Application
- 6.5 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Manufacturers Established Date
- 6.6 Global Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
- 7.2 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 7.4 North America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
- 8.2 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 8.4 Europe Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
- 9.2 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
- 10.2 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 10.4 South America Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size (2021-2032)
- 11.2 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Post-Polycythemia Vera Myelofibrosis (PPV-MF) Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.1.4 Novartis AG Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Merck & Co Inc
- 12.2.1 Merck & Co Inc Company Information
- 12.2.2 Merck & Co Inc Business Overview
- 12.2.3 Merck & Co Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.2.4 Merck & Co Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.2.5 Merck & Co Inc Recent Developments
- 12.3 AbbVie Inc
- 12.3.1 AbbVie Inc Company Information
- 12.3.2 AbbVie Inc Business Overview
- 12.3.3 AbbVie Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.3.4 AbbVie Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.3.5 AbbVie Inc Recent Developments
- 12.4 Sun Pharma Advanced Research Company Ltd
- 12.4.1 Sun Pharma Advanced Research Company Ltd Company Information
- 12.4.2 Sun Pharma Advanced Research Company Ltd Business Overview
- 12.4.3 Sun Pharma Advanced Research Company Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.4.4 Sun Pharma Advanced Research Company Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.4.5 Sun Pharma Advanced Research Company Ltd Recent Developments
- 12.5 Promedior Inc
- 12.5.1 Promedior Inc Company Information
- 12.5.2 Promedior Inc Business Overview
- 12.5.3 Promedior Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.5.4 Promedior Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.5.5 Promedior Inc Recent Developments
- 12.6 NS Pharma Inc
- 12.6.1 NS Pharma Inc Company Information
- 12.6.2 NS Pharma Inc Business Overview
- 12.6.3 NS Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.6.4 NS Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.6.5 NS Pharma Inc Recent Developments
- 12.7 MEI Pharma Inc
- 12.7.1 MEI Pharma Inc Company Information
- 12.7.2 MEI Pharma Inc Business Overview
- 12.7.3 MEI Pharma Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.7.4 MEI Pharma Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.7.5 MEI Pharma Inc Recent Developments
- 12.8 MedImmune LLC
- 12.8.1 MedImmune LLC Company Information
- 12.8.2 MedImmune LLC Business Overview
- 12.8.3 MedImmune LLC Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.8.4 MedImmune LLC Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.8.5 MedImmune LLC Recent Developments
- 12.9 JW Pharmaceutical Corp
- 12.9.1 JW Pharmaceutical Corp Company Information
- 12.9.2 JW Pharmaceutical Corp Business Overview
- 12.9.3 JW Pharmaceutical Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.9.4 JW Pharmaceutical Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.9.5 JW Pharmaceutical Corp Recent Developments
- 12.10 Italfarmaco SpA
- 12.10.1 Italfarmaco SpA Company Information
- 12.10.2 Italfarmaco SpA Business Overview
- 12.10.3 Italfarmaco SpA Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.10.4 Italfarmaco SpA Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.10.5 Italfarmaco SpA Recent Developments
- 12.11 Incyte Corp
- 12.11.1 Incyte Corp Company Information
- 12.11.2 Incyte Corp Business Overview
- 12.11.3 Incyte Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.11.4 Incyte Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.11.5 Incyte Corp Recent Developments
- 12.12 Gilead Sciences Inc
- 12.12.1 Gilead Sciences Inc Company Information
- 12.12.2 Gilead Sciences Inc Business Overview
- 12.12.3 Gilead Sciences Inc Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.12.4 Gilead Sciences Inc Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.12.5 Gilead Sciences Inc Recent Developments
- 12.13 F. Hoffmann-La Roche Ltd
- 12.13.1 F. Hoffmann-La Roche Ltd Company Information
- 12.13.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.13.3 F. Hoffmann-La Roche Ltd Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.13.4 F. Hoffmann-La Roche Ltd Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.13.5 F. Hoffmann-La Roche Ltd Recent Developments
- 12.14 CTI BioPharma Corp
- 12.14.1 CTI BioPharma Corp Company Information
- 12.14.2 CTI BioPharma Corp Business Overview
- 12.14.3 CTI BioPharma Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.14.4 CTI BioPharma Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.14.5 CTI BioPharma Corp Recent Developments
- 12.15 Celgene Corp
- 12.15.1 Celgene Corp Company Information
- 12.15.2 Celgene Corp Business Overview
- 12.15.3 Celgene Corp Revenue in Post-Polycythemia Vera Myelofibrosis (PPV-MF) Business (2021-2026)
- 12.15.4 Celgene Corp Post-Polycythemia Vera Myelofibrosis (PPV-MF) Product Portfolio
- 12.15.5 Celgene Corp Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst